These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 14871161)

  • 21. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia.
    King DJ; Link CG; Kowalcyk B
    Psychopharmacology (Berl); 1998 May; 137(2):139-46. PubMed ID: 9630000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amisulpride: a review of its use in the management of schizophrenia.
    Curran MP; Perry CM
    Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Focus on quetiapine.
    Green B
    Curr Med Res Opin; 1999; 15(3):145-51. PubMed ID: 10621920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
    Findling RL; McKenna K; Earley WR; Stankowski J; Pathak S
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):327-42. PubMed ID: 23083020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amisulpride: a review of its use in the management of schizophrenia.
    McKeage K; Plosker GL
    CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement without impairment: a review of clinical data for quetiapine in the treatment of schizophrenia.
    Tandon R
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S15-20. PubMed ID: 12832945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone.
    Larmo I; de Nayer A; Windhager E; Lindenbauer B; Rittmannsberger H; Platz T; Jones AM; Altman C;
    Hum Psychopharmacol; 2005 Dec; 20(8):573-81. PubMed ID: 16175656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spotlight on amisulpride in schizophrenia.
    Curran MP; Perry CM
    CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quetiapine--efficacy in different domains.
    Sharma T
    Eur Neuropsychopharmacol; 2001 Oct; 11 Suppl 4():S385-90. PubMed ID: 11587885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia.
    Sirota P; Pannet I; Koren A; Tchernichovsky E
    Hum Psychopharmacol; 2006 Jun; 21(4):227-34. PubMed ID: 16783811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia.
    Emsley RA; Buckley P; Jones AM; Greenwood MR
    J Psychopharmacol; 2003 Jun; 17(2):210-5. PubMed ID: 12870569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function.
    Rainer M; Haushofer M; Pfolz H; Struhal C; Wick W
    Eur Psychiatry; 2007 Sep; 22(6):395-403. PubMed ID: 17482432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder.
    Rupnow MF; Greenspan A; Gharabawi GM; Kosik-Gonzalez C; Zhu Y; Stahl SM
    Curr Med Res Opin; 2007 Nov; 23(11):2815-22. PubMed ID: 17910802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.